English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
First Psychedelic Trip: An Honest Guide to Your First Ceremony
So you’re thinking about your first trip. Maybe it’s ayahuasca at a retreat in the Sacred Valley, maybe psilocybin in a legal container in the Netherlands, maybe San Pedro on a mountainside in Ecuador. Whatever the medicine, the questions tend to be the same, and most of them don’t get answered honestly online. People either oversell the bliss or overplay the terror. The truth sits somewhere in between, and it’s a lot more interesting than either extreme. I’ve spent years around plant medicine — sitting in ceremony, interviewing facilitators, talking to people the morning after their first night with the brew. What follows is what I wish someone had handed me before my first time. It’s not a substitute for talking to a trained facilitator, and it definitely isn’t a recommendation that you go drink something tonight. It’s the conversation you’d have with a friend who’s been around the block, over coffee, the week before you fly out. The cliché is that everyone goes to ayahuasca for trauma. That’s not wrong, but it’s thin. The reality is messier. Some people come because antidepressants stopped working. Some are in recovery from alcohol or opioids and have tried every twelve-step room within driving distance. Some are quietly stuck — a job they hate, a marriage running on fumes, a creative block they can’t name. A few are simply curious, and curiosity is a perfectly legitimate reason if you’re honest about it. What master plants — ayahuasca, San Pedro, iboga, psilocybin mushrooms — seem to do, in the right container, is make the things you’ve been avoiding impossible to keep avoiding. That’s the mechanism, more or less. The medicine doesn’t hand you wisdom on a plate. It removes the soundproofing between you and your own life. Whether that turns into healing or just a rough night depends on a lot of factors, most of which you can influence before you ever sit down. If you’re researching psychedelics for addiction specifically, know that the evidence base has grown considerably in the last few years. Trials at Johns Hopkins, NYU, and Imperial College London have shown meaningful results for alcohol use disorder, tobacco dependence, and treatment-resistant depression. Ibogaine — a powerful, longer alkaloid from the iboga root — has a particular reputation among opioid users for interrupting withdrawal. None of this is magic. All of it requires real preparation and real aftercare. Readiness isn’t a feeling. It’s a checklist. And it’s worth running through honestly because the consequences of skipping it are paid in the ceremony itself, not in some abstract future. If you can’t check most of those boxes, the right move is usually to wait. The retreats will still be there in six months. So will you, ideally in better shape to receive what the work is offering. People want the trip report. Fair enough. Here’s an honest sketch, with the caveat that no two ceremonies are alike and yours will be its own thing. With ayahuasca, the first hour is mostly waiting. You drink something that tastes like tar mixed with regret, you sit on your mat, you wonder if you got a weak cup. Then a shift — colors behind the eyelids, a body buzz, the icaros (the shaman’s songs) suddenly feeling like they’re happening inside your chest rather than across the room. Somewhere between forty minutes and two hours in, the medicine takes the wheel. What follows varies wildly. Some people see geometric visions and rivers of light. Others get plain, brutal clarity about their own behavior with no visuals at all. Many purge — vomiting, crying, sometimes both — and in the tradition, the purge is the point, not a side effect. You might love your facilitator, hate them, forget they exist. Time gets weird. Three hours feels like three minutes or three lifetimes. Then, slowly, you come back, the music sounds normal again, and you sleep harder than you have in years. Psilocybin is gentler in profile, usually shorter (four to six hours), and tends to feel more like a deep emotional reorientation than a metaphysical encounter. San Pedro is long and warm — eight to twelve hours, often outdoors, more grounded than transcendent. Ibogaine is its own beast: a long, often physically uncomfortable internal review that can last a day and a half. Pick the medicine that matches what you’re actually trying to do, not the one with the best Instagram aesthetic. The plant-medicine space has exploded in the last few years, and not everyone running a retreat should be. Here’s what to look for, and what to walk away from. Price isn’t a perfect signal, but it tells you something. A week-long ayahuasca retreat in Peru typically runs between $1,500 and $3,500 once you include accommodation and ceremonies. Significantly cheaper often means corners cut on safety; significantly pricier sometimes just means nicer linens. Look at what’s included, not the sticker. If I could change one thing about how first-timers approach plant medicine, it would be this: stop treating the ceremony as the destination. The ceremony is the starting gun. The race is everything that happens in the six to twelve months afterward. Integration is the unglamorous work of taking what the medicine showed you and actually changing how you live. That might mean leaving a relationship, getting sober, starting therapy, switching careers, repairing something with a parent you haven’t spoken to in eight years. None of that happens because you drank a brew. It happens because, after the brew, you finally have the clarity and the nerve to start — and you put structure around that clarity before it fades. Practical integration looks like: a weekly therapist familiar with psychedelic work, an integration circle (many run free or low-cost online), a journaling practice, time in nature, no new big decisions in the first two weeks, and a deliberate slowdown on the substances and stimuli that you’d normally use to numb out. The first month is fragile. Protect it. Plant medicine isn’t for everyone, and the people in this space who pretend otherwise are either selling something or haven’t sat with enough first-timers. Some people have life-changing experiences. Some have hard, useful experiences that take years to fully metabolize. A small number have experiences that genuinely destabilize them, which is why screening and aftercare matter as much as they do. Going in with realistic expectations — neither dread nor breathless hope — is the single best predictor I’ve seen of a good outcome. If you’ve read this far and the pull is still there, take it seriously. Talk to people who’ve done it. Read the contraindications twice. Save a little longer if you have to, so you can go somewhere properly run rather than wherever’s cheapest. For readers who want to take this further, a range of vetted ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly. The medicine, if it’s for you, will still be waiting.
Colorado Greenlights Ibogaine Clinics: What This Means for Addiction Recovery
Something quietly significant just happened in Colorado. The state has authorized a small handful of pilot ibogaine clinics — a move that, depending on how it plays out, could mark the first real domestic foothold for one of the most studied (and most feared) plant medicines in the addiction-recovery world. If you've been watching the psychedelic policy space, you probably saw this coming. If you haven't, this is the moment to start paying attention. Ibogaine sits in a strange corner of the plant medicine conversation. It doesn't have the cultural cachet of ayahuasca or the gentle PR of psilocybin. It's harder. Longer. More medically demanding. And yet, for people stuck in opioid dependence — the kind of dependence that has eaten lives, marriages, careers — it has a reputation that nothing else in the psychedelic catalog can quite match. So when a U.S. state opens the door, even a crack, the people who need this medicine notice immediately. The short version: a small number of pilot clinics have been authorized to administer ibogaine in a regulated, medically supervised setting. This is not full legalization, not a free-for-all, and not anything that resembles the underground network of providers that has existed in the U.S. for years. It's a controlled program, built on the back of Colorado's Natural Medicine Health Act — the 2022 ballot measure that legalized psilocybin therapy and left room for other plant medicines to be considered later. Ibogaine wasn't part of the original psilocybin rollout. It's being added now because the case for treating opioid use disorder with a single, carefully supervised dose has gotten harder to ignore. Kentucky considered putting opioid settlement money toward ibogaine research a couple of years back. Texas has funded clinical studies. Veterans groups have been loud and persistent about what they've experienced in Mexico and Costa Rica. Colorado is the first state to actually open clinics on its own soil. What the pilot looks like in practice: medical screening, including cardiac evaluation, because ibogaine can affect heart rhythm; supervised dosing in a clinical environment; trained staff on hand for the full duration of the experience, which can run twelve to twenty-four hours; and integration support afterward. This is not a retreat in the jungle. It's a medical model. Ibogaine comes from the root bark of the iboga shrub, used for centuries in Bwiti spiritual practice in Gabon and surrounding regions. It's a powerful psychoactive — closer to a deep, hours-long internal review of your own life than to the visionary state most people associate with ayahuasca or mushrooms. People describe it as watching their entire history played back, with the parts they've avoided suddenly impossible to look away from. The reason addiction researchers care is more concrete than that, though. A single dose of ibogaine appears to reset something in the brain's opioid receptors. People who've been physically dependent for years frequently come out the other side without the acute withdrawal that normally takes weeks to push through. That doesn't mean they're cured — and anyone who tells you otherwise is selling something — but it gives them a window. A clean break. A chance to do the slower work of recovery without their body screaming at them. The why-now part is simpler. The opioid crisis hasn't gotten better. Fentanyl has made the math worse. Conventional treatments — methadone, buprenorphine, abstinence-based programs — work for some people and fail for many others. Policymakers are starting to ask uncomfortable questions about what else might be on the table, and ibogaine, despite its risks, keeps coming up in those conversations. Here's where I get a little stern, because the enthusiasm around ibogaine sometimes outruns the honesty. Ibogaine is not a safe substance in the casual sense. It can cause cardiac arrhythmia, including a specific risk called QT prolongation that has killed people who took it without proper screening. It interacts badly with a long list of medications. It is brutally hard on the body even when nothing goes wrong — the experience is exhausting, often nauseating, and emotionally pulverizing. The reason medical supervision matters isn't theater. It's because the difference between a transformative session and a medical emergency can come down to an EKG that nobody bothered to do. The underground providers who do this well know this. The ones who don't have left a trail of deaths that the field doesn't talk about enough. If you're considering ibogaine — for yourself, or for someone you love — these are the non-negotiables: Anybody who waves any of these off isn't a provider you want. The Colorado decision matters because it changes the geography of access. For the past two decades, Americans seeking ibogaine for addiction have almost all traveled out of the country — Mexico mostly, sometimes Costa Rica, occasionally further. That's expensive, logistically difficult, and for someone in active addiction, sometimes impossible. A domestic option, even a limited one, removes a barrier that has kept this medicine out of reach for people who arguably need it most. It also signals something about where U.S. psychedelic policy is heading. Oregon went first with psilocybin. Colorado followed with a broader framework. Now ibogaine is in that framework. The pattern is clear: states are moving faster than the federal government, and they're moving toward regulated, medical-adjacent access rather than full decriminalization. Whether that's the right model is its own debate. But it's the model that's winning. For readers thinking about plant medicine more broadly — ayahuasca for depression, psilocybin for end-of-life anxiety, San Pedro for general reorientation — what's happening with ibogaine is worth tracking. It's the canary in the coal mine for whether a serious, medically rigorous, U.S.-based plant medicine industry can actually exist. If Colorado's pilot goes well, other states will copy it. If it goes badly — if there are deaths, scandals, regulatory overreach — the whole field will feel the chill. This is the question I get most often from people considering ibogaine, and there's no clean answer. The Colorado pilot is small. Capacity will be limited. Costs are not yet clear, but ibogaine treatment, even in less regulated environments, runs in the five-figure range and insurance won't touch it. The waitlist, when it opens, is likely to be long. Meanwhile, established providers in Mexico have been doing this work for years. The good ones — and there are good ones — have medical screening protocols that rival what U.S. clinics will offer. They have integration programs. They have track records you can actually check. The trade-off is that you're navigating an unfamiliar country, often during a vulnerable moment in your life, with less regulatory recourse if something goes wrong. My honest take: if you have time, watch how the Colorado program unfolds over the next year. If you don't have time — if the person who needs this is in acute crisis — research the international providers carefully, talk to people who've been there, ask hard questions about safety protocols, and don't let cost be the only filter. For readers who want to explore what's actually available, a range of carefully vetted ibogaine and plant medicine retreats can be browsed on our marketplace here. Ibogaine isn't a miracle and it isn't for everyone. But for the right person, in the right setting, with the right preparation, it's one of the most powerful tools we have for breaking the grip of addiction. Colorado just made that tool a little easier to reach. That's worth paying attention to.
Ibogaine for Addiction Recovery: What Nobody Tells You Before You Go
Somebody messages me about ibogaine roughly once a week. Usually it's a parent. Sometimes it's the person themselves, three or four relapses deep, exhausted, scrolling at 2 a.m. The question is almost always the same: is this the thing that finally works? I don't have a clean answer. Nobody honest does. But after years of covering plant-medicine retreats and sitting with people on both sides of an ibogaine experience — the ones who came home changed and the ones who came home disappointed — I can at least tell you what the conversation actually looks like when you strip away the marketing. If you're considering ibogaine for addiction, master plants more broadly, or any psychedelic-assisted recovery option, this is the piece I wish someone had handed me when I started asking around. Ibogaine is an alkaloid extracted from the root bark of the iboga shrub, which grows in the rainforests of Gabon and Cameroon. In traditional Bwiti practice it's used in initiation ceremonies — long, intense, ritually structured. In the West, it found a second life starting in the 1960s when a heroin user named Howard Lotsof took it recreationally and noticed his withdrawal symptoms had vanished. That accidental discovery is, more or less, why we're still talking about it. The substance does something genuinely unusual. It seems to reset opioid receptors and interrupt the physical craving cycle in a way no other compound reliably does. People walk out of a single session and the dope-sickness — the bone-deep, vomit-inducing kick of opioid withdrawal — is just gone. That part isn't hype. Multiple observational studies and the lived testimony of thousands of people line up on this point. What ibogaine isn't, though, is a magic eraser. The compound buys you a window. What you do with that window is the actual work. The clearest case for ibogaine is opioid dependence: heroin, fentanyl, oxycodone, methadone (though methadone is notoriously tricky and many clinics won't accept active methadone patients without a long taper). There's also growing interest in its use for stimulant addiction, alcohol use disorder, and certain trauma presentations, though the evidence base for those is thinner. Here's where I'll be blunt. Ibogaine is not the right call for everyone with an addiction problem. People I've watched do well with it tend to share a few traits: People who struggle tend to be the opposite: looking for a quick fix, isolated, financially overextended by the trip itself, with no plan for week two. Ibogaine carries real cardiac risk. It can prolong the QT interval — a measurement of heart electrical activity — and in rare cases this triggers fatal arrhythmias. Deaths have happened. Most of them, when investigated, involved underlying heart conditions that weren't screened for, or interactions with other substances (especially opioids still in the system, or stimulants). A reputable clinic will require, at minimum: a recent EKG, comprehensive bloodwork including liver and kidney panels, a medical history review with an actual doctor, and a clear protocol for stabilizing you off short-acting opioids before dosing. If a place will take your money without all of that, walk away. I mean it. That's not a retreat, that's a liability waiting to happen. The experience itself is also genuinely hard. Most people describe it in two phases: a visionary phase that can last six to ten hours, often involving life review, encounters with deceased relatives, and a kind of forced confrontation with one's choices; followed by an introspective phase that can stretch another twenty-four to forty-eight hours where you're awake, exhausted, processing. It's not euphoric. It's not fun. People who go in expecting an ayahuasca-style mystical opening are usually surprised by how clinical and demanding it feels. Ibogaine is a Schedule I substance in the United States, which means treatment there isn't legally available. The main destinations for medically supervised ibogaine are Mexico, Costa Rica, Portugal, the Netherlands (in some grey-area contexts), and New Zealand, where it's a prescription medicine. South Africa and Brazil also have programs. Pricing varies wildly. Expect a range that looks something like this: Cheaper isn't always worse, and more expensive isn't always better. What you're really paying for is medical infrastructure and the quality of the people sitting with you. Ask specifically: who is the medical director, what's their background, and how many sessions has the staff facilitated? If you can't get clear answers, that tells you something. People often lump ibogaine in with ayahuasca, psilocybin, and other psychedelic healing modalities. They're related but not interchangeable. Ayahuasca tends to work more emotionally and somatically — it's a brilliant tool for trauma, depression, and stuck life patterns, and there are people who've gotten sober through ayahuasca retreats, but it doesn't have ibogaine's specific receptor-resetting effect on opioid withdrawal. Psilocybin shows real promise for alcohol use disorder and tobacco cessation, with clinical trials backing it up. It's gentler, more accessible, and increasingly legal in pockets of the U.S. and elsewhere. For someone with a milder substance issue or a co-occurring depression, psilocybin-assisted work may be a better starting point than flying to Tijuana for a heart-screened ibogaine flood dose. The honest comparison: ibogaine is the most powerful tool for breaking active opioid dependence physically. Ayahuasca and psilocybin are more flexible tools for the psychological and spiritual layers underneath. Some of the better retreats now combine them — ibogaine first to interrupt the cycle, then ayahuasca or 5-MeO some days later to deepen the integration. This is where most ibogaine stories quietly go wrong. The clinic experience ends, you fly home, and there's a window of about four to six weeks where cravings stay reduced and you feel a kind of clarity people sometimes describe as a clean slate. After that window, life resumes. The job stress, the difficult relationship, the boredom, the social circles that were built around using — none of that has changed because you were in Mexico for a week. The people who stay clean long-term, in my experience, do at least three of these things in the months after treatment: Skipping the aftercare and treating the trip as the cure is the single most common pattern of failure I see. The retreat is maybe twenty percent of the work. The rest happens at home, on ordinary Tuesdays. For the right person, in the right circumstances, with the right preparation and the right follow-through — yes, ibogaine can be one of the most powerful interventions available for addiction. I've watched it pull people out of decade-long opioid dependence in a way that nothing else touched. That's not nothing. That's, in some cases, a life saved. For the wrong person — looking for a shortcut, ignoring the cardiac screening, with no plan for week two — it's an expensive and risky disappointment at best, and genuinely dangerous at worst. If you're seriously weighing this, take your time. Talk to people who've actually been through it (not just the clinic's curated testimonials). Get an EKG before you even start shopping. Read about Bwiti and the cultural roots of the medicine — it matters. And if something here speaks to you, the range of ibogaine and plant-medicine recovery retreats discussed across this space can be browsed on our marketplace here. Whatever you decide, decide it slowly. The plants have been around a long time. They'll still be there next month.
Blocked by Reddit? Why Real Psychedelic Wisdom Lives Off the Forums
Picture this. You're three weeks out from booking an ayahuasca retreat, you've got a browser tab open to some psychedelic subreddit you found at 1 a.m., and instead of the trip report you came for, you hit a wall: You've been blocked by network security. Cool. Very helpful. Thanks for that. If you've spent any time researching plant medicine online, you know the loop. You read a few articles, you get curious, you start scrolling forums, and pretty soon you're knee-deep in strangers' anecdotes about ayahuasca ceremonies, ibogaine flood doses, and what someone's aunt's yoga teacher said about master plants. Then a paywall, a login gate, or a security block knocks you out cold. It's annoying. But honestly? It might be the best thing that happens to your research. Because here's the truth nobody on those threads will tell you: most of the important questions about psychedelics and addiction recovery cannot be answered by a stranger with a username like DMTDreamer420. They need to be answered by people who actually sit with this medicine — facilitators, integration therapists, doctors, and yes, journalists who've done the legwork. So let's talk about what good research actually looks like when you're considering a retreat. I'm not anti-forum. I've read thousands of trip reports over the years, and some of them are gorgeous, honest, and useful. But forums are a terrible primary source for the decision you're trying to make. They overrepresent the dramatic — the breakthroughs and the breakdowns — and underrepresent the boring middle, which is where most ceremony experiences actually live. Nobody posts a thread titled “My ayahuasca night was quiet and I cried a little and then I went to bed.” But that's a lot of nights. Forums also flatten context. Someone raves about a retreat in Iquitos without mentioning they have no trauma history, no medications, and a meditation practice going back fifteen years. You read it and assume your experience will look the same. It won't. Plant medicine meets you where you are, not where the poster was. And then there's the bigger problem: a lot of what gets repeated as fact on psychedelic forums is just… wrong. Half-truths about MAOIs and SSRIs. Confident claims about ayahuasca curing depression in one ceremony. Bad information about ibogaine and heart safety. Real harm has come from people taking forum advice as medical guidance. So when Reddit blocks you, treat it as a small gift and go find better sources. Most people researching a psychedelic retreat are circling a handful of real questions, even if they don't phrase them clearly to themselves. Let me name them, because clarity helps. These are excellent questions. They are also questions a forum can only half-answer. The first one needs a doctor or a prescriber who understands serotonergic interactions. The second needs an honest read of the research plus a frank look at your own history. The third needs reviews, references, and a real conversation with the facilitator. The fourth needs first-person writing from people who can describe an inner experience with some craft. The fifth needs an integration coach or therapist. Choosing where to drink ayahuasca, or where to sit with psilocybin or San Pedro, is the single most consequential decision in this whole process. Set, setting, and shaman — the old triad — still holds. Here's a saner approach than scrolling. You can do all of this through emails and phone calls. You don't need a forum thread to vet a retreat — you need ninety minutes of your own focused time and a willingness to ask uncomfortable questions. One of the most common reasons people end up researching psychedelic retreats is addiction — to alcohol, opioids, stimulants, or the quieter compulsions that don't get a name. The research here is genuinely interesting, and worth understanding before you book anything. Ibogaine has the longest track record for interrupting opioid dependence. It's not a cure, and it carries real cardiac risk that demands medical screening and on-site monitoring. Done well, it can collapse a withdrawal syndrome that would otherwise take weeks. Done badly, it kills people. The gap between those two outcomes is almost entirely about screening, dosing, and supervision. Ayahuasca shows up in addiction recovery research as well, particularly through the work coming out of Brazil and Canada. Participants in observational studies report meaningful reductions in alcohol and cocaine use after ceremonial work, often paired with months of integration. Psilocybin has its own growing literature, with trials at Johns Hopkins and NYU showing real signal for alcohol use disorder and tobacco cessation. None of this is magic. All of it depends on what happens before and after the ceremony as much as during. If you're considering plant medicine for addiction, the honest framing is this: the medicine can crack something open. Whether that opening becomes lasting change is about therapy, community, and your own daily choices over the following year. Anyone selling you a one-and-done miracle is selling something else. You'll see the phrase master plants tossed around a lot in the psychedelic space, often without explanation. In the Amazonian tradition, master plants are species considered to be teachers — not because they're psychoactive, necessarily, but because dieting them in a structured, isolated way is said to transmit specific knowledge and qualities. Ayahuasca is one. So are bobinsana, chiric sanango, ajo sacha, and others most retreat-goers never encounter. This matters because it reframes what a ceremony is. You're not taking a drug to get an experience. You're entering a relationship with a plant that has its own intelligence and its own terms. You can take or leave that framing philosophically, but the curanderos and ayahuasqueros who serve this medicine take it seriously, and how you show up shapes what you get. A respectful, prepared participant tends to have a different night than a curious tourist looking for a peak experience. The retreat starts weeks before you arrive. Most reputable ayahuasca centers will send you a dieta — restrictions on certain foods, alcohol, drugs, and often sexual activity for a set window before and after. Follow it. It's not superstition. The interactions are real, and the discipline of preparation is itself part of the work. Beyond the dieta, give yourself time. Cut back on screens. Sit with yourself in silence even if it's uncomfortable, especially if it's uncomfortable. Write down what you're hoping for and what you're afraid of. Tell a trusted person what you're doing. Line up a therapist or integration coach for after — not three weeks after, the week of your return. Insights have a half-life. Catch them while they're warm. And manage expectations. You may have the night of your life. You may have a hard, frightening, nauseating night that makes no obvious sense for months. Both are part of the territory. Plant medicine doesn't owe you a particular experience, and chasing one is the surest way to miss what's actually being offered. Not entirely. Used wisely, they're useful for finding names of facilitators, reading honest trip reports, and getting a feel for how people talk about their experiences. Just don't use them to answer your safety questions, your medical questions, or your should I do this at all question. Those deserve better sources. If you want to keep exploring, read peer-reviewed research from MAPS and Johns Hopkins, follow a few writers who've sat with this work for decades, and talk to people in person — at integration circles, recovery meetings, or through facilitators directly. For readers ready to start comparing actual options, a curated set of ayahuasca and plant-medicine retreats can be browsed on our marketplace here, which at least cuts out the part where Reddit slams a door in your face. The decision is still yours. But you'll be making it with better information than a blocked thread can offer.
Psilocybin and Alzheimer's: What That Viral Case Report Actually Says
Late last month, a single case report set the internet on fire. An 80-something woman with a decade of Alzheimer's — largely non-verbal, incontinent, dependent for nearly everything — was given five grams of dried psilocybin mushrooms. Within days, she was speaking spontaneously. Walking better. Dressing herself. Cracking jokes, even. Cue the headlines. Groundbreaking drug trial. Reverses dementia. Memory restored. Splashy stuff. The kind of story that ricochets across social feeds before anyone reads past the lede. Here's the thing, though. It wasn't a trial. There was no control group, no blinded raters, no standardised cognitive scales. It was one patient, in one private psychiatric office in São Paulo, observed by people who already knew her. That doesn't make it worthless — case reports have started plenty of legitimate research programs — but it's a long, long way from a treatment. And the psychiatrist who ran the sessions is the first to say so. The patient had been deteriorating for ten years, with the last five marked by what clinicians call hypofunction — flat affect, monosyllabic speech, chronic incontinence, difficulty swallowing, almost no spontaneous communication. Her son approached her psychiatrist, Marcos Lago, with the idea of trying psilocybin. After conversations with the legal guardian and caregivers about risks and the complete absence of evidence in advanced Alzheimer's, they went ahead. The first session used five grams of dried mushrooms of the so-called Enigma strain. According to the report, she had acute autonomic activation, profuse sweating, suspected hyperthermia, and fell into a prolonged sleep-like state. The next morning, something shifted. She began producing what the authors describe as spontaneous autobiographical speech — she was telling stories from her own life, unprompted. Over the following weeks, the changes kept stacking up. Bladder control returned. She walked with more confidence. She dressed herself. She made eye contact. A second session, this time at three grams, reportedly brought more expressivity, facial mimicry, even humour. Caregivers — people who'd watched her decline for years — said she was someone they recognised again. You can see why the press jumped on it. The story is irresistible. A cheap, ancient natural compound bringing a grandmother back from the long fog of Alzheimer's — it writes itself. The problem is that almost every word in those headlines was doing work the underlying paper couldn't support. It wasn't a clinical trial. It was private psychiatric care, written up afterward. There were no blinded independent assessors. No standardised dementia scales administered at fixed intervals. No control. The dose itself wasn't a dose in the pharmaceutical sense — dried mushrooms vary wildly in potency, and you can't convert mushroom weight into milligrams of psilocybin with any confidence. The patient's improvement, however striking, was reported through clinical observation and caregiver accounts. Those are valuable, but they're not the same thing as evidence in the regulatory sense. Lago himself is unusually clear about this. He calls the case a research hypothesis, not a treatment recommendation. He resists the framing that any of this proves efficacy. What it does, he argues, is raise a legitimate question worth investigating properly — and that's a much more modest, much more honest claim than what most of the coverage made of it. This is where things get interesting, and a bit complicated. Lago is a São Paulo psychiatrist in private practice. He says he has supervised roughly 400 psilocybin sessions involving around 200 adults — a number that would raise eyebrows almost anywhere in the world, and definitely in Brazil, where psilocybin is a proscribed substance under the country's health authority. Most of those sessions, he says, weren't conventional medical treatment. They happened within what he describes as a philosophical and contemplative framework — meditation, self-knowledge, the study of consciousness. He's also associated with a religious organisation, Associação Cruz de Ankh, which he argues operates within the constitutional protections for freedom of belief and religious practice that Brazil affords. Is that a clean legal shield? Lago doesn't claim it is. He's careful to draw lines between approved medical treatment, formal research, private psychiatric care, and ceremonial religious practice — categories that, in his words, aren't interchangeable. The Brazilian situation echoes what's happened with ayahuasca, where decades of court rulings carved out space for religious use of the brew. Whether psilocybin will follow a similar path is unsettled. If you're someone watching a parent slip into dementia, or you're considering plant medicine for your own reasons, it's worth being blunt about what this case does and doesn't establish. What it does do is suggest that psilocybin's effects on neuroplasticity, neuroinflammation, and default-mode network activity — the stuff researchers actually study — might be worth examining in dementia populations. That's a real scientific question. It deserves real trials with proper design, not viral tweets. Step back from Alzheimer's for a moment. The reason a case like this captures imagination is that it touches a broader hope: that psychedelics and master plants might unstick things that conventional medicine can't. Addiction. Depression that won't lift. Trauma stored in the body for decades. The default-mode network humming on the same anxious loop year after year. The evidence for some of these uses is genuinely promising. Psilocybin for treatment-resistant depression has produced striking results in Phase 2 trials. Ibogaine for opioid addiction has decades of underground data and now mounting clinical interest. Ayahuasca's effects on depression and substance use have been studied in religious-use cohorts for years. None of this is magic — the responsible researchers are quick to point out non-responders, adverse events, and the need for psychological support before and after. But there's a real signal in the noise. People do, sometimes, change in ways they couldn't access through talk therapy or SSRIs alone. The mechanism isn't fully understood. The set, setting, and integration matter enormously. And the people who do best are usually the ones who treated the experience as the start of work, not the end of it. For readers thinking about this for their own reasons — not Alzheimer's, but the everyday stuck places that bring most people to plant medicine — a few unglamorous suggestions. None of this is meant to talk you out of anything. Plant medicine has helped a lot of people address things that nothing else touched. It's just that the help tends to come to people who showed up prepared, not to people who showed up looking for a shortcut. The honest read on the São Paulo case is somewhere between the breathless headlines and the dismissive scoff. It's one observation. It's interesting. It probably justifies a properly designed trial in carefully screened patients with mild-to-moderate cognitive impairment, with continuous medical monitoring and standardised outcome measures. It does not justify a wave of families giving five-gram doses of unregulated mushrooms to elderly relatives at home. Please don't. What Lago seems to want — and what the field actually needs — is the boring, slow, methodical version of this story. Trials. Data. Replications. Honest reporting of the cases that didn't work alongside the ones that did. The interesting thing about psilocybin research right now is that, after decades of prohibition, that boring slow version is finally starting to happen. If reading all this has left you curious about the broader landscape of plant-medicine work — psilocybin retreats, ayahuasca ceremonies, ibogaine programs — a range of vetted psychedelic and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it with eyes open.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
When Someone You Love Is Heading to an Ayahuasca Retreat: A Friend's Guide
A friend tells you, with that particular mix of excitement and nerves, that they've booked an ayahuasca retreat. Maybe it's somewhere in the Peruvian jungle. Maybe it's a weekend ceremony two hours from where you live. Either way, your stomach does a small flip. You've heard things. You've read things. And now someone you actually care about is about to drink a bitter brown brew and, depending on which corner of the internet you trust, either heal their deepest wounds or have a psychological emergency in a hammock. This piece is for you — the worried friend, sibling, partner, or parent. Not the person going. The person watching them go. Because the conversations you have in the weeks before, during, and after matter more than most people realize, and there's almost nothing written for the people on your side of the equation. Before you say anything to your friend, sit with what you're actually feeling. Worry is the obvious one. But underneath it there's often something else — judgment, jealousy, fear of being left behind, or a quiet conviction that this is a phase they need to be talked out of. Those feelings aren't wrong. They're just not useful information for your friend right now. The plant medicine world has a credibility problem with outsiders, and for understandable reasons. The headlines tend to be the bad ones: someone died at an unregulated retreat, someone came back changed in worrying ways, someone got scammed. What doesn't make the news is the much larger group of people who go, have a hard but meaningful experience, and quietly integrate it into a better-functioning life. Both stories are true. Which one your friend ends up in depends heavily on choices they're making right now. So your job isn't to talk them out of it. It's to help them go in clear-eyed. Big difference. Ayahuasca is a brew made from two Amazonian plants — a vine (Banisteriopsis caapi) and a leaf (usually Psychotria viridis) — that together produce a powerful psychedelic experience lasting roughly four to six hours. It's been used for centuries by Indigenous peoples in the Amazon basin in ceremonial contexts, and over the past two decades it's gone global. There are now ayahuasca retreats in dozens of countries, ranging from tiny family-run centers in Peru to slick wellness operations charging five-figure prices. The experience itself is usually intense. Most people vomit (it's called la purga and is considered part of the medicine, not a side effect to minimize). Many cry. Some have visions, some don't. People often describe confronting memories, relationships, and patterns they've been avoiding for years. The next morning they tend to be quiet, tender, and unsure how to talk about what just happened. This is the part friends and family often miss: ayahuasca isn't recreational. People aren't going for fun. The vast majority are going because something in their life — addiction, depression, grief, a stuck pattern, unprocessed trauma — isn't responding to anything else they've tried. Understanding that reframes the whole conversation. This is where you can actually be useful. Most people booking their first ayahuasca retreat don't know what to look for, and a thirty-minute conversation with you asking the right questions could save them from a bad situation. Here's what a reputable retreat does, and what should make you both nervous: Encourage your friend to read reviews on multiple sources, not just the retreat's own website. Ask them if they've talked to anyone who actually attended. If they haven't, that's a reasonable thing to suggest. You don't need to become a plant medicine expert overnight. But there are a few questions worth raising, gently, before they leave: Are they on any medications? SSRIs and SNRIs (the most commonly prescribed antidepressants) need to be tapered off well in advance — usually four to six weeks — under medical supervision, because mixing them with ayahuasca can trigger serotonin syndrome, which is genuinely dangerous. Same for MAOIs, lithium, tramadol, and several other drugs. If your friend hasn't talked to a doctor about this, push them to. This isn't woo-woo caution; it's basic chemistry. What are they actually hoping for? Not in a therapist voice. Just in an honest friend voice. People who go in expecting a magic erasure of their problems often come out disappointed or destabilized. People who go in curious, with realistic expectations, tend to fare better. What's their support system after? The week after a ceremony is when integration happens. If they're flying home on a red-eye and back at a stressful job Monday morning with nobody to talk to, that's a setup for a rough landing. Can you be one of the people they call? You probably won't hear much. Most retreats discourage or prohibit phones, and that's a good thing. Resist the urge to spiral if your texts go unanswered for a week. They're fine. They're probably sitting in a circle eating plantains and trying to process what happened the night before. If you're genuinely concerned — say, if they have a serious mental health history you've been worried about — it's reasonable to know the name and location of the retreat and to have an emergency contact number. Any legitimate operation will provide this. But assume things are fine unless you have real reason to think otherwise. This is the part nobody prepares friends for. Your friend may come home glowing, full of insights they can't quite articulate. They may come home quiet and a little raw. They may come home convinced they need to leave their job, end their relationship, or move to South America. Some of these conclusions will turn out to be wisdom. Some will turn out to be the temporary intensity of a psychedelic experience that hasn't settled yet. The most useful thing you can do is listen without judging and without rushing them toward big decisions. The first month is for integrating, not for restructuring a life. If they're talking about quitting everything within a week of coming home, you can lovingly suggest waiting ninety days before making anything permanent. That advice is consistent across nearly every experienced integration therapist in this space. Watch, gently, for warning signs: persistent sleep problems, inability to function, intrusive thoughts that don't fade, or anything resembling psychosis. These are rare but real, and a trauma-informed therapist who understands psychedelics is the right resource — not the retreat's WhatsApp group, not Reddit, not you alone. Sometimes watching a friend go through this stirs something in you. That's worth noticing without immediately acting on it. Plant medicine isn't right for everyone, and it isn't right at every moment in a person's life. But if your friend's experience leaves you genuinely curious — not envious, not FOMO-driven, but curious — there's no harm in learning more on your own timeline. For readers who want to take this further, a range of vetted ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Mostly, though, your job right now is just to be the steady person in your friend's life. The one who didn't lecture them, didn't catastrophize, didn't pretend to know more than they did. That's a more valuable role than you might think. The plant does its own work. Your work is showing up for the person on the other side.
When the Medicine Says You're Done: Knowing It's Time to Hang Up the Pipe
There's a phrase that floats around psychedelic circles, usually said with a half-smile: when you get the message, hang up the phone. It's attributed to Alan Watts, though he was talking about meditation more than mushrooms. The idea has stuck around because it gets at something most retreat brochures won't tell you. Plant medicine isn't supposed to be forever. At some point — if the work is actually working — you put it down. This is the conversation nobody seems to want to have when you're three ceremonies deep into your ayahuasca journey and wondering if you should book the next retreat. So let's have it. Here's the thing about ayahuasca, psilocybin, ibogaine, and the rest of the master plants: they're tools. Useful, sometimes astonishing tools. But a hammer isn't a lifestyle. And the longer you're in the psychedelic world, the more you start to notice the people who've been chasing the next ceremony for fifteen years and don't seem any lighter for it. I've sat in circles with people on their thirtieth ayahuasca ceremony who still cry about the same wound from their childhood. I've also met people who drank twice, integrated for two years, quietly rebuilt their relationship with their father, and never went back. Both paths exist. The difference between them isn't usually the medicine — it's what people did with the message after they got it. Psychedelic healing is not a subscription service. The plants don't owe you anything after the first profound encounter. Sometimes the most radical move you can make as a psychonaut is to stop being one. This is the question I get asked most often by readers somewhere between their second and fifth ceremony. They've felt the breakthrough. They've cried into the bucket. They've seen the architecture of their own avoidance patterns laid bare. And then they wonder — is that it? Or is there more? There's no clean answer, but there are signals. People who've genuinely finished their psychedelic work tend to report things like: None of these alone means you're done. All of them together, persistently, probably does. One thing that comes up over and over with people who've spent a decade in the psychedelic scene is a particular flavor of restlessness. They call it spiritual seeking, but underneath it often looks a lot like the same compulsion that drove their drinking or their workaholism before they found plant medicine. The object changed. The hunger didn't. This is worth paying close attention to if you're using psychedelics in the context of addiction recovery. Plant medicine for addiction is showing real promise in clinical settings — ibogaine for opioid dependency, psilocybin for alcohol use disorder, ayahuasca for a broad range of compulsive patterns. But the substance you took to get free can quietly become the next thing you depend on, and the retreat circuit is set up to reward that. Ask yourself, honestly: am I going back because the work calls me, or because regular life feels too small now? Both are valid feelings. Only one is a reason to drink the brew again. Integration gets thrown around as a buzzword. Most people think it means journaling for two weeks after a retreat and joining an integration circle on Zoom. That's a fine start. It's not the whole thing. Real integration — the kind that lets you put the medicine down — looks more like: If you've done these things and the medicine still calls you, fine — go drink. But if you haven't, another ceremony is probably not what's missing. I'm not arguing that one and done is the right model for everyone. Some people need several ayahuasca ceremonies before the deepest layer cracks open. Some people benefit from a single annual sit the way others benefit from an annual silent retreat — as a check-in, a recalibration. Indigenous traditions have always understood ayahuasca as something you return to across a lifetime, but in a specific cultural context with specific guardrails. That's different from a Western seeker booking four retreats a year because they liked the feeling. Reasons that make sense for going back: Reasons that should make you pause: The most healed people I've met in this world are often the ones who've stopped talking about it. They drank ayahuasca seven years ago. It changed them. They don't post about it. They don't recommend retreats unprompted. They've folded the experience so completely into who they are that it's no longer a separate chapter — it's just part of the texture of their life. That's the goal, I think. Not endless seeking. Not collecting ceremonies the way people used to collect frequent flyer miles. Just becoming someone who lives well, who is kinder to the people around them, who doesn't need a master plant to access their own depth anymore. The medicine, if it's doing its job, makes itself obsolete in your life. That's not failure. That's graduation. If you're sitting with the question of whether to attend another retreat, sit with it for longer than you think you need to. Two months. Six months. A year. The plants will still be there. The retreat centers will still be there. The question isn't going anywhere. And in the meantime, the answer often arrives on its own — sometimes as a clear pull toward ceremony, more often as a quiet realization that you already have what you came for. For readers who do feel that clear pull and want to take this further, a range of vetted ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it from a settled place — not from the restlessness that brought you to the medicine in the first place.
Loneliness and Letting Go: What Plant Medicine Teaches About Sitting Alone
Loneliness has a way of showing up uninvited. You can be in a packed maloca with twenty other people, the icaros rising and falling around you, and still feel like you’re the only person in the room. Anyone who has sat with ayahuasca, psilocybin, or any of the other master plants long enough has bumped into this. It’s one of the quieter teachings of plant medicine — and one of the least talked about in the brochures. If you’re researching a psychedelic retreat right now, you’ve probably read plenty about ego dissolution, visionary states, and breakthroughs around addiction or depression. What gets mentioned less often is the raw, unglamorous experience of feeling deeply alone partway through a ceremony, and what to actually do with that feeling. So let’s talk about it honestly. Plant medicines tend to strip the furniture out of the room. The distractions you normally lean on — your phone, your work, your relationships, the steady hum of being busy — aren’t available in ceremony. What’s left is you, the medicine, and whatever you’ve been avoiding. For a lot of people, that includes a baseline loneliness they didn’t realise they were carrying. Ayahuasca in particular has a reputation for pulling buried emotional material to the surface. Grief over people who’ve died. Old breakups that never really healed. The specific ache of childhood loneliness. A kambo session can do something similar in a more physical key. Psilocybin sometimes opens it more gently, like a slow tide. The substance varies; the underlying revelation often doesn’t — you’ve been lonely for longer than you admitted. This isn’t a malfunction. It’s the point. Plant medicine for addiction, depression, and stuck life patterns works in part by showing you what you’ve been numbing. Loneliness is one of the most common things people numb. Alcohol numbs it. Endless work numbs it. Scrolling numbs it. Take the numbing away and there it is, waiting. Here’s where it gets interesting. Many people leave a retreat reporting that they still spend plenty of time alone — but the loneliness has loosened its grip. That’s not a coincidence. Somewhere in the ceremony, the wiring between solitude and suffering got rerouted. Being alone is a circumstance. Being lonely is a story you tell yourself about that circumstance. The story usually goes something like: I’m alone because something is wrong with me. I’m alone because nobody really sees me. I’m alone and that means I’ll always be alone. Sit in ceremony long enough and these stories tend to show themselves for what they are — old, repetitive, often inherited. I’ve watched people during integration circles describe this moment of recognition with something close to relief. Not because the loneliness vanished, but because they finally saw it wasn’t a fact about reality. It was a habit of mind. Habits of mind can be worked with. “Letting go” is one of those phrases that gets repeated until it’s lost any meaning. On a retreat brochure it sounds simple. In ceremony, at 2 a.m., with your chest aching and the room spinning, it sounds like a cruel joke. So what does it actually mean? It doesn’t mean forcing yourself to stop feeling something. That’s suppression dressed up in spiritual language, and the medicine sees right through it. Letting go, in the way the master plants seem to teach it, is closer to this: you stop fighting what’s already there. You let the feeling be in the room with you without immediately trying to fix it, name it, or push it away. A facilitator I respect describes it as relaxing your grip without dropping the object. The loneliness is still there. You’re still holding it. But you’re not strangling it, and it’s not strangling you. Strange things happen when you can do that even for thirty seconds. The feeling moves. It changes shape. Sometimes it dissolves entirely. Sometimes it just becomes more bearable. If you’re seriously considering a psychedelic retreat — particularly one involving ayahuasca, ibogaine, or psilocybin — it’s worth doing some homework on this specific territory before you arrive. The people who navigate loneliness well in ceremony are usually the ones who saw it coming. One more thing worth saying: if your loneliness is severe, if it’s tangled up with serious depression, suicidal thinking, or active addiction, please don’t treat a retreat as a first line of help. Talk to a clinician familiar with psychedelic-assisted approaches. Reputable retreat centres will screen for this and will tell you honestly if they’re not the right setting for where you are right now. The good ones turn people away. Be wary of the ones who don’t. Here’s the part that surprised me the first time I encountered it. The people who do this work seriously — who sit with ayahuasca more than once, who take their integration seriously, who work with master plants over years rather than weekends — often end up describing solitude as something they actively want. Not all the time. Not exclusively. But as a real, nourishing part of their life. That’s the turn. Loneliness was the symptom; solitude becomes the medicine. You learn that you can be alone with yourself and the company isn’t bad. That’s a profound thing for someone who has spent decades running from it. It’s also one of the more durable outcomes I’ve seen from this work — more durable, often, than the visionary content that gets all the attention. None of this means a retreat is the right move for you. Only you can weigh that, and the weighing matters. But if loneliness is part of what’s pushing you to consider plant medicine — for addiction, for depression, for the dull background ache of being human — know that you’re in good company. Most of the people in the maloca next to you are quietly working with some version of the same thing. If something in this resonates and you want to explore further, a range of curated ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Take your time choosing. The right setting matters more than most first-timers realise.
Sitting With Grief: A Contemplative Path Through Loss and Disconnection
There's a particular kind of heaviness a lot of people are carrying right now. It doesn't have a name or a date attached. No funeral, no breakup, no obvious wound — just a low static of sorrow humming underneath the ordinary day. You wake up tired in a way sleep won't fix. You scroll through the news and feel something tighten in your chest, then immediately distract yourself. You miss something you're not sure you ever actually had. I've come to think this kind of grief is real, and that it has a source — even if it resists easy explanation. It's what it feels like to be a living, sensing creature inside systems that are quietly coming apart: ecological, social, relational, spiritual. And it's what it feels like to keep moving too fast to actually register any of it. The body knows. The body always knows. The question is whether we're willing to listen. Modern life has been organized around a story so old we've stopped noticing it: that humans are somehow separate from the natural world. Rivers became infrastructure. Forests became timber. Soil became a substrate for yield curves. Even our own attention has been turned into a commodity to be harvested. The story has produced extraordinary things — antibiotics, air travel, the ability to read this sentence on a glowing rectangle — but it has also produced a rupture. A quiet, civilizational tear between us and the living systems that actually keep us alive. Here's the thing. The body keeps a different ledger than the culture does. Something in us still knows we're not separate — that we're made, quite literally, from the water, air, and slow accumulated intelligence of ecosystems that have been writing themselves for millions of years. When that knowing is overridden long enough, grief is one of the ways it surfaces. Not as a tidy emotion but as a fog. As anxiety that won't quite resolve. As a craving for meaning that no amount of productivity quite satisfies. People sometimes call this ecological grief or climate grief. Those names point at something real but they're also too narrow. The grief I'm describing is broader — it's the grief of disconnection itself. From land. From neighbors. From the slow rhythms of bodies and seasons. From a sense of being part of something larger than the next quarter. There's an image from Buddhist cosmology I keep coming back to: Indra's Net. Picture a vast web stretching infinitely in every direction. At each intersection of the web, a jewel. And in each jewel, the reflection of every other jewel. Nothing stands alone. Each point contains and is contained by the whole. Thich Nhat Hanh called this interbeing — the recognition that a flower contains the cloud that rained on it, the soil that fed it, the sun that reached toward it across ninety-three million miles. What's interesting is that this isn't only a contemplative teaching anymore. Ecology, systems science, complexity theory — they're all saying versions of the same thing in different vocabularies. Cut down a forest in one region and rainfall patterns shift hundreds of miles downwind. Disturb a soil microbiome and the mental health of the people eating from it changes. Pull on any thread and the whole fabric moves. Separateness was always the illusion. We just built a civilization on top of it and called it common sense. The crises we're living through — climate disruption, species collapse, the slow unraveling of social trust — aren't separate problems to be solved one at a time. They're different expressions of the same foundational confusion. Which means the response can't only be technical. It has to include a different way of feeling ourselves inside the world. This is the part that took me years to understand, and I'll say it plainly: grief is evidence of connection. It means you haven't gone fully numb. It means that somewhere beneath the coping, the scrolling, the forward motion, something in you still recognizes what's being lost. You wouldn't grieve what you weren't already, in some sense, part of. We turn away from grief by staying busy. By optimizing. By staying productive enough not to feel it. And in doing so we lose something important — not because suffering is virtuous, but because grief, when we can actually be present with it, keeps us in contact with what matters. Grief is the feeling of caring. And caring is what makes it possible to act from something other than fear, obligation, or habit. This is one reason so many people who sit with plant medicines like ayahuasca, psilocybin, or San Pedro describe their experience as grief work rather than recreation. The medicines don't deliver insight on a platter. They tend to dissolve the armor we've built around feelings we've been outrunning — sometimes for decades. What rises up is often the very thing we've been organizing our lives to avoid. And underneath it, frequently, is love. The love of what's real. The love of being part of something. Contemplative traditions have understood for a long time what modern life keeps forgetting: presence is a skill. The ability to remain with what's actually happening — pleasant, painful, confusing, all of it — isn't a personality trait. It's trained. You build it the same way you build any other capacity: by doing it, repeatedly, badly at first, until something in you changes. A few practices that genuinely help with this kind of grief: What all of these share is a particular quality. The willingness to be with what is, rather than only what you wish were there. To let grief and beauty and uncertainty share the same room without insisting one cancel the others. Something else changes when you start practicing this way. Time itself starts to feel different. The compressed, optimized, every-minute-monetized time of modern productivity loosens its grip a little. Underneath it, you start to notice an older rhythm — cyclical rather than linear, attentive to recurrence, growth, loss, return. The time of seasons. Of bodies healing. Of forests recovering. Of grief itself, which moves on its own schedule and doesn't take meeting requests. To slow down enough to feel that rhythm is to reconnect with the depth from which any meaningful response comes. Quick action from a place of disconnection mostly produces more of what created the problem in the first place. Slower action — even slightly slower — from a place of genuine contact has a different quality. It tends to be wiser. Less frantic. More likely to actually help. This is, in part, why the integration period after a retreat matters as much as the ceremony itself. The ceremony can shake something loose. But it's the slow weeks and months afterward — the sitting, the journaling, the long walks, the difficult conversations — where the shift actually settles into a life. If you've been quietly researching ayahuasca or another plant-medicine retreat, and you're not entirely sure why, I'd gently suggest this: the unnameable grief might be part of the reason. Most people don't book a retreat because everything is going great. They book one because something has been asking for attention that the ordinary tools of life haven't been able to address. A few honest things worth knowing before you go: Indra's Net works in both directions. If every point in the web reflects every other, then changes in how we understand ourselves don't stay private. They move outward. They shape which questions get asked, which trade-offs get accepted, which futures feel possible. Personal practice and collective transformation aren't separate categories. They're the same web, felt from different angles. When grief is held rather than avoided, it tends to move. Not vanish — grief doesn't really vanish — but transform. It softens into something closer to love. The love of what's real. The love of what's actually here. The love of what we're genuinely part of, whether we remember it or not. For readers who feel pulled to take this work further in a structured setting, a range of curated plant-medicine and ayahuasca retreats can be browsed on our marketplace here. Whatever you choose, the practice — really — is the same. Come back to what's here. Come back to what you're already part of. Again and again, with the heart as open as you can manage.
Microdosing vs. Macrodosing LSD: What a Bi-Weekly 100µg Routine Really Does
Every few weeks, someone posts a version of the same question on a psychedelic forum: what if I just took 100 micrograms of LSD every two weeks, indefinitely? Not a microdose. Not a heroic dose. Something in between — enough to feel, not enough to dissolve the furniture. The replies range from cautious enthusiasm to outright alarm, and honestly, both reactions have merit. This question sits at an interesting crossroads of the broader psychedelics conversation. It's not quite the territory of master plants and ceremony — there's no curandero, no icaros, no dieta. But it borrows from that world's logic: the idea that altered states, used with intention and rhythm, can shift something stuck. Whether that idea holds up at 100 micrograms every fourteen days is the question worth chewing on. First, the dose itself. One hundred micrograms of LSD is what most people would call a light-to-moderate recreational dose. It's well above microdose territory (typically 5–20µg), and well below what veteran psychonauts consider a full psychedelic experience (200µg and up). At 100µg, expect a noticeable shift in perception — color saturation cranked up, mild visual drifting, time elongating in odd ways, and a general loosening of the usual mental scaffolding. Emotionally, the effect varies wildly by person and setting. Some people report a soft, warm openness that lasts six to eight hours. Others find themselves wrestling with anxious loops or unexpected memories. The dose is high enough that you cannot reliably work, drive, parent, or hold a serious conversation with someone outside the experience. It's also high enough that something genuinely psychedelic can happen — insights, releases, the occasional emotional avalanche. So when someone proposes doing this every two weeks, they're not proposing a maintenance routine. They're proposing twenty-six full-ish psychedelic experiences a year. That's a significant amount of inner work, even if each individual session feels modest. LSD has unusually fast and steep tolerance. Take a dose today, take the same dose tomorrow, and you'll feel almost nothing. The serotonin 5-HT2A receptors that LSD binds to downregulate quickly, and they take roughly two weeks to fully reset. This is why the bi-weekly cadence keeps surfacing — it's the shortest interval at which the drug reliably still works at full strength. That biological reality is also a warning sign. The fact that your receptors need fourteen days to recover suggests that something meaningful is happening to your neurochemistry each time. Researchers studying psychedelic-assisted therapy generally space sessions weeks or months apart for exactly this reason — not because the effects wear off, but because the integration window matters more than the experience itself. There's also the question of long-term receptor health. The honest answer is that we don't have great longitudinal data on people doing moderate LSD doses every two weeks for years. Small studies on classic psychedelics suggest the compounds themselves are physiologically gentle. But behavioral patterns, mood regulation, and the way you relate to your own emotions over time — that's a different question entirely. Here's the thing that gets lost in the dose-and-frequency debate. The psychedelic experience itself is not the work. The work is everything that happens in the days and weeks after — the journaling, the conversations, the slow rewiring of habits and beliefs that the session pointed toward. If you trip every two weeks, you essentially never finish integrating one experience before starting the next. You're constantly opening new material without closing the previous loop. For some people this feels generative — like an ongoing dialogue with their own psyche. For others it becomes a kind of psychedelic treadmill, where each session promises insight and the next one obscures it. Therapists who work with psychedelic-assisted recovery generally suggest one of two patterns: What's notable is that almost nobody in the clinical or traditional plant-medicine world recommends the middle path — moderate doses on a frequent schedule. There's a reason. The middle path tends to give you the disruption without the depth, and the frequency without the digestion. None of this is to dismiss the impulse. People reach for a routine like this for understandable reasons. They've had a powerful experience once and want to keep that door open. They're struggling with depression, addiction, or a stuck life pattern, and conventional treatment hasn't moved the needle. They've read the headlines about psilocybin trials for treatment-resistant depression and want to design their own version. Some of these motivations are legitimate. The research on classic psychedelics for depression, addiction, and end-of-life anxiety is genuinely promising. Compounds like LSD, psilocybin, ibogaine, and ayahuasca seem to do something that standard antidepressants don't — they create a brief window of neural plasticity in which long-held patterns become temporarily flexible. But that plasticity is also the catch. A window of openness without a plan is just a draft. If you keep prying the window open every two weeks without ever putting anything new in the room, you may just be letting the wind howl through. The substance is the catalyst. You are the chemistry. If you're seriously thinking about regular psychedelic use, here's what tends to separate the people who get something lasting from the people who plateau: This is where the traditional plant-medicine world has something to offer the rationalist psychonaut, even if the latter rolls their eyes at icaros and feathered headdresses. A ceremony is not just a fancy delivery system for a molecule. It's a container — a set of practices, relationships, and rituals that hold the experience and frame what comes after. You don't have to fly to Peru to access this. Plenty of people work with experienced facilitators in their own country, in legal or quasi-legal settings, with thoughtful preparation and follow-up. The point isn't the location. The point is that someone other than you is holding the structure, which lets you actually surrender into the experience instead of half-tripping while also playing the role of guide. For people whose interest in regular dosing comes from a genuine therapeutic need — addiction, trauma, depression that won't lift — a few well-held retreat experiences will usually go further than a year of solo bi-weekly sessions. They're more expensive in the short term and less expensive in every other way. For readers who want to explore that direction, a range of curated psychedelic and plant-medicine retreats can be browsed on our marketplace here. Is doing 100µg of LSD every two weeks dangerous? Probably not physiologically, for a healthy adult with no contraindications, no SSRIs in the mix, and no family history of psychosis. Is it likely to deliver the transformation people hope for? Probably not either. The cadence is too frequent for deep integration and too potent for sustainable maintenance. It splits the difference in a way that rarely serves anyone for long. If you've been considering this kind of routine, the more useful question isn't what dose, what frequency. It's what am I actually trying to change, and what's the smallest, most considered intervention that might move it? Sometimes the answer is microdosing under supervision. Sometimes it's one carefully prepared retreat. Sometimes it's therapy without any substances at all. The molecule is rarely the bottleneck. What you do with the opening it creates — that's where everything lives.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
